Attar.) Trent II - fege 6 
9212-036* 
9303-037* 
9303-038 
9303-039 
9303-040 
9303-041* 
9303-042* 
(T/IGD/Cystic Fibrosis) 
Welsh, Michael J.; Howard Hughes Medical Institute, Iowa City, Iowa, and Smith, Alan E.; 
Genzyme Corporation, Framingham, Massachusetts; Cystic Fibrosis Gene Therapy Using an 
Adenovirus Vector In Vivo Safety and Efficacy in Nasal Epithelium. 
RAC Approval: 12-4-92/NIH Approval: 4-16-93 
Minor Modification: 10-18-93 
(T/C/Glioblastoma Multiforme) 
Culver, Kenneth W.; Iowa Methodist Medical Center, Des Moines, Iowa, Van Gilder, John C.; 
University of Iowa, Iowa City, Iowa, Berger, Mitchel; University of California, San Francisco, 
California, and Prados, Michael; University of Washington, Seattle, Washington; Gene Therapy for 
the Treatment of Recurrent Glioblastoma Multiforme with In Vivo Tumor Transduction with the Herpes 
Simplex Thymidine Kinase Gene/Ganciclovir System. 
RAC Approval: 3-1-93/NIH Approval: 4-16-93 
Minor Modification: 7-13-94 
(M/EBV-CTL) 
Heslop, Helen E.; Brenner, Malcolm K.; and Rooney, Cliona; St. Jude Children’s Research Hospital, 
Memphis, Tennessee; Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T 
Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow 
Grafts. RAC Approval: 3-2-93/NIH Approval: 4-16-93 
Minor Modification: 8-31-94 
(M/BM) 
Brenner, Malcolm K.; Krance, Robert; Heslop, Helen E.; Santana, Victor; and Ihle, James; St. Jude 
Children’s Research Hospital, Memphis, Tennessee; Assessment of the Efficacy of Purging by Using 
Gene-Marked Autologous Marrow Transplantation for Children with Acute Myelogenous Leukemia in 
First Complete Remission. 
RAC Approval: 3-2-93/NIH Approved: 4-16-93 
(T/V/C/Renal Cell) 
Simons, Jonathan; Johns Hopkins Oncology Center, Baltimore, Maryland; Phase I Study of Non- 
Replicating Autologous Tumor Cell Injections Using Cells Prepared With or Without Granulocyte- 
Macrophage Colony Stimulating Factor Gene Transduction in Patients with Metastatic Renal Cell 
Carcinoma. 
RAC Approval: 3-1-93/NIH Approval: 12-2-93 
(T/IGD/Cystic Fibrosis) 
Wilraott, Robert W. and Whitsett, Jeffrey, Children’s Hospital Medical Center, Cincinnati, Ohio, 
and Trapnell, Bruce; Genetic Therapy, Inc., Gaithersburg, Maryland; v4 Phase I Study of Gene 
Therapy of Cystic Fibrosis Utilizing a Replication Deficient Recombinant Adenovirus Vector to Deliver 
the Human Cystic Fibrosis Transmembrane Conductance Regulator cDNA to the Airways. 
RAC Approval: 3-2-93/NIH Approval: 4-16-93 
Minor Modification: 8-31-94 
(T/IGD/Cystic Fibrosis) 
Boucher, Richard C. and Knowles, Michael R.; University of North Carolina, Chapel Hill, North 
Carolina; Gene Therapy for Cystic Fibrosis Using El Deleted Adenovirus: A Phase I Trial in the Nasal 
Cavity. 
RAC Approval: 3-2-93/NIH Approval: 10-7-93 
Minor Modification: 2-17-94 
Minor Modification: 9-30-94 
CLOSED: 10-94 
[494] 
Recombinant DNA Research, Volume 20 
